Alexion Pharmaceuticals, Inc. (ALXN) Tops Q1 EPS by 4c; Boosts Outlook
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Join SI Premium – FREE
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported Q1 EPS of $0.65, $0.04 better than the analyst estimate of $0.61. Revenue for the quarter came in at $338.9 million versus the consensus estimate of $336.56 million.
Alexion Pharmaceuticals, Inc. sees FY2013 EPS of $2.87-2.97, versus prior guidance of $2.82-2.92 and the consensus of $2.90. Alexion Pharmaceuticals, Inc. sees FY2013 revenue of $1.505-1.520 billion, versus prior guidance of $1.490-1.505 billion and the consensus of $1.51 billion.
For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.
Alexion Pharmaceuticals, Inc. sees FY2013 EPS of $2.87-2.97, versus prior guidance of $2.82-2.92 and the consensus of $2.90. Alexion Pharmaceuticals, Inc. sees FY2013 revenue of $1.505-1.520 billion, versus prior guidance of $1.490-1.505 billion and the consensus of $1.51 billion.
For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
